Modern Myeloma Therapy + Sustained Minimal Residual Disease–Negative = (Functional) Cure!
This review discusses how negativity for minimal residual disease (MRD) after combinatorial therapies is a strong predictor of longer progression-free survival and overall survival in newly diagnosed patients. Additionally, it emphasizes the need for standardized MRD assessment protocols and incorporating MRD monitoring into routine clinical practice to improve treatment outcomes for myeloma patients. The authors also highlight the potential of Blood-based MRD assays to improve clinical outcomes.